Company News: Celgene and Abraxis BioScience

Share this content:
New Jersey-based biotech Celgene announced an agreement to purchase Abraxis BioScience, a biotech focused on cancer treatments, for $2.9 billion. Abraxis BioScience markets Abraxane, a chemotherapy treatment option for metastatic breast cancer, which netted $314.5 million in 2009, down from $335.6 in 2008, according to an Abraxis annual report.
Share this content:
Scroll down to see the next article